Kazia Therapeutics (KZIA) vs Quantum Cyber N.V. (QUCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Quantum Cyber N.V. (QUCY) over the past year, gaining 24.4% versus a loss of 11.2%. Quantum Cyber N.V. is the larger company by market cap ($113.5 million vs $102.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KZIA | QUCY |
|---|---|---|
| Share price | $8.93 | $1.35 |
| Market cap | $102.04M | $113.49M |
| 1-day change | +1.25% | -2.88% |
| YTD return | +29.61% | +20.54% |
| 1-year return | +24.37% | -11.18% |
| 5-year return | -98.30% | — |
| EPS (TTM) | $-6.85 | $-2.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.40 | $4.93 |
| 52-week low | $4.86 | $0.30 |
| Distance from 52-week high | -48.68% | -72.62% |
| Analyst consensus | none | none |
| Avg. price target upside | +216.46% | +566.67% |
| Average volume | 262.75K | 690.79K |
| Shares outstanding | 11.43M | 84.07M |
| Employees | 6 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed QUCY by 35.6 percentage points over the past year.
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Quantum Cyber N.V.
QUCY stock →Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
KZIA vs QUCY FAQ
Which is bigger, Kazia Therapeutics or Quantum Cyber N.V.?
Quantum Cyber N.V. (QUCY) is larger, with a market capitalization of $113.49M compared with $102.04M for Kazia Therapeutics (KZIA).
Which stock has performed better over the past year, KZIA or QUCY?
KZIA returned +24.37% over the past 12 months, compared with -11.18% for QUCY (price return, excluding dividends). Past performance does not predict future results.
Are Kazia Therapeutics and Quantum Cyber N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.